|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1600 20TH STREET, NW |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20009 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 32362-12
|
||||||||
|
6. House ID# 321020000
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Noyan Eyigor |
Date | 4/20/2023 8:45:57 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BAN
16. Specific lobbying issues
Financial reform, crypto currency legislation, bills slated for hearing and mark-up in House Financial Services Committee on 2/8 and 2/28, bills to deregulate securities underwriting, executive compensation reform, preventing future bank failures.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bart |
Naylor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CIV
16. Specific lobbying issues
Lobbying for a rule making banning forced arbitration in financial products.
17. House(s) of Congress and Federal agencies Check if None
Consumer Financial Protection Bureau (CFPB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Martha |
Perez-Pedemonti |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
H.R. 6107 Stop Corporate Capture Act, regulatory reform, potential cryptocurrency legislation, Regulatory reform, CSS Lobby meeting, Stop Corporate Capture Act, REINS Act, access to justice and product safety, Consumer Products - children, S.2710 Open App Markets Act and S.2992 American Innovation and Choice Online Act, antitrust/competition policy, anti-monopoly issues, protecting consumers against forced arbitration. Commercial Surveillance Rule-making, Financial Data privacy bill - oppose, Kids internet privacy and safety bills, forthcoming comprehensive/kids privacy bills, privacy issues.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Consumer Financial Protection Bureau (CFPB), White House Office, Federal Trade Commission (FTC), Natl Economic Council (NEC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bart |
Naylor |
|
|
|
Elizabeth |
Skerry |
|
|
|
Martha |
Perez-Pedemonti |
|
|
|
Matthew |
Kent |
|
|
|
Susan |
Harley |
|
|
|
Emily |
Peterson-Cassin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code GOV
16. Specific lobbying issues
Banning congressional insider trading, H.J.Res.1 -- constitutional amendment to overturn Citizens United., Ban on congressional stock trading (TRUST in Congress Act), House rules package regarding the Office of Congressional Ethics (H.Res.5), Ban congressional stock trading activity (consensus bill), HUMBLE Act (no bill number yet), Office of Congressional Ethics, rules change (H.Res.5), Stop Foreign Money in American Elections Act (no bill number yet), Ban congressional stock trading (no bill number yet), Office of Congressional Ethics (OCE), Prohibition on Financial Trading on Government Property Act (no bill number yet), Prohibition on Financial Trading on Government Property Act (no bill number yet), Ban congressional stock trading, Banning congressional stock trading, Judiciary Act of 2023, DISCLOSE Act, End congressional stock trading (HR 345, HR 1679, no bill number in Senate yet), Judiciary Act (no bill number yet), ZOMBIE Act (no number yet),
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Craig |
Holman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S 4204 and HR 1976, Medicare for All, private equity in health care, Oversight of private equity in health care, Healthcare Ownership Transparency Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Eagan |
Kemp |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
Heat stress, outline remarks for speaking at NACOSH meeting re: OSHA Heat rule process failings, met with Rep. Scholten and Rep Martinez - intro discussion of heat stress, Sunlight on Workplace Harassment bill.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Occupational Safety & Health Administration (OSHA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Juley |
Fulcher |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
insulin pricing; drug launch prices; access terms for medicines w/ R&D funded by USG; R&D cost transparency; alternative pharmaceutical R&D models; pandemic vaccine manufacturing, IRA implementation, telehealth and pharmaceuticals, U.S. government support for the mRNA Hub program; pandemic vaccine manufacturing, , FDA policies impacting drug prices and spending; executive licensing authorities to lower drug prices , IRA drug price negotiation implementation, IRA drug price negotiation implementation, U.S. government support for the mRNA Hub , Bayh-Dole domestic manufacturing requirements, Biosimilar Red Tape Elimination Act, executive licensing and demonstration authorities to lower drug prices; IRA drug price negotiation implementation, IRA drug price negotiation implementation, IRA drug price negotiation implementation, IRA drug price negotiation implementation, IRA drug price negotiation implementation; Biosimilar Red Tape Elimination Act , Prescription Drug Access and Affordability Act, Prescription Drug Price Relief Act, S.79 (Interagency Patent Coordination and Improvement Act); S.113 (Prescription Pricing for the People Act); S.142 (Preserve Access to Affordable Generics and Biosimilars Act); S.148 (Stop STALLING Act); S.150 (Affordable Prescriptions for Patients Act), S.79 (Interagency Patent Coordination and Improvement Act); S.113 (Prescription Pricing for the People Act); S.142 (Preserve Access to Affordable Generics and Biosimilars Act); S.148 (Stop STALLING Act); S.150 (Affordable Prescriptions for Patients Act; e, TRACK Act, TRACK Act, U.S. government support for the mRNA Hub program, U.S. government support for the mRNA Hub program; public vaccine manufacturing, Affordable Pricing for Taxpayer-Funded Prescription Drugs Act, Affordable Pricing for Taxpayer-Funded Prescription Drugs Act; FDA-PTO coordination, covid vaccine pricing; executive licensing and demonstration authorities to lower drug prices; U.S. government support for the mRNA Hub program, insulin pricing legislation, IRA drug price negotiation implementation, IRA drug price negotiation implementation; Emergency Access to Insulin Act; S.79; S.113; S.142; S.148; S.150; IRA negotiation delay periods and other measures; U.S. government support for the mRNA Hub program; IRA negotiation delay periods, IRA drug price negotiation implementation; NDAA drug pricing and licensing; insulin cost & pricing legislation; S.79; S.113; S.142; S.148; S.150; IRA negotiation delay periods and other measures; U.S. government support for the mRNA Hub program, NDAA drug pricing, licensing and transparency requirements; IRA negotiation delay periods and other measures; U.S. government support for the mRNA Hub program , U.S. government support for the mRNA Hub program, executive licensing authorities to lower drug prices, Insulin for All Act; IRA drug price negotiation implementation, Insulin for All Act; IRA drug price negotiation implementation; legislation to strengthen IRA drug pricing provisions; U.S. government support for the mRNA Hub program, IRA drug price negotiation implementation, IRA drug price negotiation implementation and legislative improvements, legislation to strengthen IRA drug pricing provisions, NDAA medicines licensing, pricing and contract transparency provisions; Insulin for All Act, PASTEUR Act, Pharmaceutical Research Transparency Act; IRA drug price negotiation implementation; U.S. government support for the mRNA Hub program; access to U.S. government funded medicines and vaccines, Protecting Consumer Access to Generic Drugs Act; U.S. government support for the mRNA Hub program; access to U.S. government funded medicines and vaccines, U.S. government support for the mRNA Hub program; IRA drug price negotiation implementation; Emergency Access to Insulin Act, access to U.S. government funded medicines and vaccines, access to U.S. government funded medicines and vaccines, access to U.S. government funded medicines and vaccines; IRA drug price negotiation and inflationary rebate improvement legislation, access to U.S. government funded medicines and vaccines; U.S. government support for the mRNA Hub program, Affordable Insulin Now Act, Bayh-Dole march-in & royalty-free rights, Bayh-Dole march-in & royalty-free rights, IRA drug price negotiation implementation, IRA drug price negotiation implementation, NDAA biomedical R&D transparency, licensing, and pricing; access to U.S. government funded medicines and vaccines, PBM transparency Act, prescription pricing for the people act, IRA drug price negotiation implementation; IRA drug price negotiation and inflationary rebate improvement legislation, U.S. government support for the mRNA Hub program, U.S. government support for the mRNA Hub program; access to U.S. government funded medicines and vaccines.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), U.S. Agency for International Development (USAID)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Steven |
Knievel |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
tax transparency and progressive revenue raisers, Lobby meeting with Senator Warner, financial transaction taxes, tax filing simplification. Forthcoming Bright Lines Project legislation, Bright Lines project, Nonprofit hospital policies.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Robert |
Stewart |
|
|
|
Susan |
Harley |
|
|
|
Emily |
Peterson-Cassin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
BAN |
GOV |
LBR |
TAX |
ENG |
FUE |
TRD |
|
|
CIV |
HCR |
PHA |
CSP |
ENV |
TRA |
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |